Actively Recruiting

Phase 4
All Genders
NCT06940830

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

Led by Swedish Orphan Biovitrum · Updated on 2026-03-24

250

Participants Needed

27

Research Sites

184 weeks

Total Duration

On this page

Sponsors

S

Swedish Orphan Biovitrum

Lead Sponsor

P

PSI CRO

Collaborating Sponsor

AI-Summary

What this Trial Is About

The rationale for this study is to further understand and describe the long-term prophylactic effectiveness of efanesoctocog alfa in preventing joint bleeds in a real-life setting.

CONDITIONS

Official Title

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female patient with a diagnosis of haemophilia A.
  • Able to give signed informed consent and comply with study requirements.
  • Prescribed efanesoctocog alfa prophylactic treatment within 6 months before or at enrolment.
  • Received hemophilia prophylactic treatments for at least 12 months before starting efanesoctocog alfa.
  • Have documented treatment and bleeding episode data from 12 months before efanesoctocog alfa treatment until enrolment.
  • Willing to follow visit schedule and undergo study assessments including joint health scores and patient questionnaires.
  • Able and willing to document all bleeding episodes and related treatments during the study.
  • For the ultrasound subgroup, agree to annual joint ultrasound assessments.
Not Eligible

You will not qualify if you...

  • Have acquired haemophilia A or other blood clotting disorders besides hereditary haemophilia A.
  • Have a positive FVIII inhibitor result (≥0.6 Bethesda unit/mL) from medical records between switching to efanesoctocog alfa and enrolment.
  • Currently enrolled in another clinical interventional study or using an investigational drug within 3 months before enrolment.
  • Judged by the investigator as unsuitable for participation, including inability or unwillingness to perform study assessments.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 27 locations

1

Sobi Investigational Site

Zagreb, Croatia

Actively Recruiting

2

Sobi Investigational Site

Brno, Czechia

Actively Recruiting

3

Sobi Investigational Site

Ostrava, Czechia

Actively Recruiting

4

Sobi Investigational Site

Prague, Czechia

Actively Recruiting

5

Sobi Investigational Site

Bordeaux, France

Actively Recruiting

6

Sobi Investigational Site

Marseille, France

Actively Recruiting

7

Sobi Investigational Site

Montpellier, France

Actively Recruiting

8

Sobi Investigational Site

Nantes, France

Actively Recruiting

9

Sobi Investigational Site

Paris, France

Actively Recruiting

10

Sobi Investigational Site

Rennes, France

Actively Recruiting

11

Sobi Investigational Site

Rouen, France

Actively Recruiting

12

Sobi Investigational Site

Berlin, Germany

Actively Recruiting

13

Sobi Investigational Site

Bonn, Germany

Actively Recruiting

14

Sobi Investigational Site

Frankfurt am Main, Germany

Actively Recruiting

15

Sobi Investigational Site

Hamburg, Germany

Actively Recruiting

16

Sobi Investigational Site

Munich, Germany

Actively Recruiting

17

Sobi Investigational Site

Dublin, Ireland

Actively Recruiting

18

Sobi Investigational Site

Turin, Italy

Actively Recruiting

19

Sobi Investigational Site

A Coruña, Spain

Actively Recruiting

20

Sobi Investigational Site

Barcelona, Spain

Actively Recruiting

21

Sobi Investigational Site

Málaga, Spain

Actively Recruiting

22

Sobi Investigational Site

Palma de Mallorca, Spain

Actively Recruiting

23

Sobi Investigational Site

Zaragoza, Spain

Actively Recruiting

24

Sobi Investigational Site

Birmingham, United Kingdom

Actively Recruiting

25

Sobi Investigational Site

Cardiff, United Kingdom

Actively Recruiting

26

Sobi Investigational Site

London, United Kingdom

Actively Recruiting

27

Sobi Investigational Site

Manchester, United Kingdom

Actively Recruiting

Loading map...

Research Team

S

Study Physician

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here